This dataset identifies 364 patent families published between 2015 and mid-2026 that combine core validation terminology — limit of detection, method validation, analytical sensitivity — with supporting quantitative language such as calibration curve, signal-to-noise ratio and recovery, within material-analysis IPC classes. That figure counts families rather than raw document publications, which is the fairer unit because it neutralises duplicate filings across jurisdictions and continuation applications. It should be read as a scoped search result, not an exhaustive count of every patent touching these concepts.

Filing peaked at 43 families in 2021, held near that level in 2022 at 36, and has declined toward 16 in the most recent tracked year. Because publication lags filing by roughly 18 months, the most recent year always looks artificially low, so the true 2025-2026 volume is probably higher than currently visible. Even accounting for that lag, the multi-year trend from 2021 onward points to a plateau rather than continued growth.

India leads as a receiving office with 103 filings, followed by China at 93 and the United States at 73; WIPO's PCT route accounts for 29, the European Patent Office 26, and Canada 13. This distribution means a review of only US and European filings would miss the majority of documented activity. Anyone assessing freedom to operate or competitive positioning in this space should check Indian and Chinese filings directly rather than relying on US-centric databases alone.

US20210116429A1, assigned to Shimadzu and published in 2021, describes a sample analysis apparatus that automates limit-of-detection estimation. It stores a response factor for a reference compound, runs repeated GC-MS measurements, and calculates a relative standard deviation from the resulting signal strengths to derive an analysis limit value without manual calculation. It is useful as a representative example of how automated LOD estimation is being claimed at the instrumentation level rather than as a definitive boundary on the entire field.

The core G01N material-analysis classification accounts for 363 of the 364 families in this dataset, but adjacent intersections are far thinner: C12Q enzyme and DNA assay overlap sits at 44, A61K medicinal-preparation overlap at 25, B82Y nanotechnology overlap at 23, and B01L lab-apparatus overlap at only 10. These lower counts suggest that applying core validation methodology to nanosensor platforms, enzymatic assay workflows, or lab-on-chip devices carries meaningfully less claim density than the core measurement techniques themselves, making them worth a closer look for new filings.